- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00860054
Addition of Phytosterols to a Low Phytosterol Diet (phyteaux-I)
April 17, 2012 updated by: Richard E. Ostlund Jr., MD, Washington University School of Medicine
Regulation of Cholesterol Absorption: Dose Response of LDL to Phytosterols Added to a Phytosterol-Poor Diet
Studies have shown that phytosterols will lower LDL cholesterol.
Typical diets can contain between 250 to 500 mg of naturally-occurring phytosterols.
Long-term studies with phytosterol-containing products(such as margarines) have not taken into account the amounts of naturally occurring phytosterols in the diet.
This means that the effects of small amounts of natural dietary phytosterols on LDL cholesterol are not known.
In this study, we will examine the effects of phytosterols across a range of levels.
The information will likely be used to further support and possibly extend the current dietary recommendations for phytosterol use.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Men and women are eligible who:
- are of any race or ethnicity between 18 to 80 years of age;
- are in generally good health;
- have moderately elevated blood cholesterol(LDL cholesterol between 100 and 189 mg/dl)
- will eat only the foods that are provided by the center during the diet periods;
- will drink no more than 5 cups of caffeine-containing beverages a day;
- will consume no more than 1 alcoholic drink a day;
- will abstain from the consumption of alcohol for 48-hours prior to blood draw days
Exclusion Criteria:
- are younger than 18 or older than 80 years;
- have very high cholesterol(LDL cholesterol equal to or above 190 mg/dl or triglycerides equal to or above 250 mg/dl);
- have very high blood pressure(equal to or above 160 mm Hg systolic or 95 mm Hg diastolic);
- are overweight( BMI greater than 35 kg/m2)
- are taking lipid-lowering, or any other medication known to affect blood cholesterol;
- have diabetes mellitus, cancer, heart, liver and/or kidney disease, or chronic disease that might interfere with participation;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Medium Phytosterols
Diets with daily 400 mg of phytosterols
|
Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
|
Experimental: High Phytosterols Diet
Diet with 2000 mg of daily phytosterols
|
Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
|
Placebo Comparator: Low Phyto Diet
Diet with less than 100 mg of daily phytosterols
|
Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fecal cholesterol excretion
Time Frame: At the end of week 4 on each diet
|
At the end of week 4 on each diet
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
intestinal cholesterol absorption
Time Frame: At the end of week 4 on each diet
|
At the end of week 4 on each diet
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Richard Ostlund, MD, Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2006
Primary Completion (Actual)
September 1, 2006
Study Completion (Actual)
October 1, 2008
Study Registration Dates
First Submitted
March 10, 2009
First Submitted That Met QC Criteria
March 10, 2009
First Posted (Estimate)
March 11, 2009
Study Record Updates
Last Update Posted (Estimate)
April 19, 2012
Last Update Submitted That Met QC Criteria
April 17, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PBRC25025
- R01HL050420 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Merck Sharp & Dohme LLCTerminated
-
Danone JapanCompletedHealthy | Mild HypercholesterolemiaJapan